Nasus Pharma公布鼻内给药昂丹司琼(Ns003)临床前药代动力学与安全性研究积极结果

美股速递
Jun 09

Nasus Pharma Ltd. 近日宣布,其研发的鼻内给药昂丹司琼(Ns003)在临床前药代动力学与安全性研究中取得了积极成果。该研究数据表明,Ns003在实验模型中展现出良好的药代动力学特征与耐受性,为后续的临床开发奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10